Get the Stockscreener App
37.10
0.16%
-0.06
After Hours:
36.39
-0.71
-1.91%
Mineralys Therapeutics Inc stock is traded at $37.10, with a volume of 1.27M.
It is down -0.16% in the last 24 hours and up +174.61% over the past month.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.
See More
Previous Close:
$37.16
Open:
$37.1
24h Volume:
1.27M
Relative Volume:
0.93
Market Cap:
$2.46B
Revenue:
-
Net Income/Loss:
$-119.67M
P/E Ratio:
-13.59
EPS:
-2.73
Net Cash Flow:
$-97.30M
1W Performance:
+6.61%
1M Performance:
+174.61%
6M Performance:
+182.99%
1Y Performance:
+220.10%
1-Day Range:
$36.18
$37.99
1-Week Range:
$33.78
$39.20
52-Week Range:
$8.241
$39.20
Mineralys Therapeutics Inc Stock (MLYS) Company Profile
Name
Mineralys Therapeutics Inc
Sector
Industry
Phone
(888) 378-6240
Address
150 N. RADNOR CHESTER ROAD, RADNOR
Compare MLYS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MLYS
Mineralys Therapeutics Inc
|
37.10 | 2.99B | 0 | -119.67M | -97.30M | -2.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Mineralys Therapeutics Inc Stock (MLYS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-11-25 | Initiated | Jefferies | Hold |
| Jul-10-24 | Initiated | H.C. Wainwright | Buy |
| Apr-02-24 | Initiated | Goldman | Buy |
| Mar-07-23 | Initiated | BofA Securities | Buy |
| Mar-07-23 | Initiated | Credit Suisse | Outperform |
| Mar-07-23 | Initiated | Evercore ISI | Outperform |
| Mar-07-23 | Initiated | Guggenheim | Buy |
| Mar-07-23 | Initiated | Stifel | Buy |
| Mar-07-23 | Initiated | Wells Fargo | Overweight |
View All
Mineralys Therapeutics Inc Stock (MLYS) Latest News
Is Mineralys Therapeutics Inc. stock oversold or undervaluedInsider Selling & Long-Term Investment Growth Plans - baoquankhu1.vn
These 2 Healthcare Stocks More Than Doubled Recently and Could Soar Higher, According to Wall Street Analysts - MSN
How Mineralys Therapeutics Inc. stock compares to market leadersEarnings Growth Summary & Trade Opportunity Analysis Reports - baoquankhu1.vn
Srinivas Akkaraju Purchases 588,235 Shares of Mineralys Therapeutics (NASDAQ:MLYS) Stock - MarketBeat
Polar Asset Management Partners Inc. Trims Stock Holdings in Mineralys Therapeutics, Inc. $MLYS - MarketBeat
Mineralys Reports Strong Phase 3 Results for Lorundrostat in High-Risk Hypertension Patients - MSN
Parkman Healthcare Partners LLC Purchases New Holdings in Mineralys Therapeutics, Inc. $MLYS - MarketBeat
Cinctive Capital Management LP Acquires New Holdings in Mineralys Therapeutics, Inc. $MLYS - MarketBeat
Wall Street Analysts Believe Mineralys Therapeutics, Inc. (MLYS) Could Rally 149.66%: Here's is How to Trade - MSN
The Goldman Sachs Group Increases Mineralys Therapeutics (NASDAQ:MLYS) Price Target to $52.00 - MarketBeat
Mineralys Therapeutics (NASDAQ:MLYS) Director Ra Capital Management, L.P. Purchases 1,176,470 Shares - MarketBeat
Trexquant Investment LP Makes New $2.01 Million Investment in Mineralys Therapeutics, Inc. $MLYS - MarketBeat
Mineralys Therapeutics (NASDAQ:MLYS) Reaches New 52-Week HighHere's Why - MarketBeat
Mineralys Therapeutics (NASDAQ:MLYS) Given "Buy" Rating at HC Wainwright - MarketBeat
Aldosterone Synthase Inhibitors Market Outlook (2025-2032) : - openPR.com
Mineralys Therapeutics Reaches Analyst Target Price - Nasdaq
Mineralys Therapeutics stock hits all-time high at 37.42 USD By Investing.com - Investing.com Australia
Mineralys Therapeutics (NASDAQ:MLYS) Trading 5.3% Higher Following Analyst Upgrade - MarketBeat
Why Mineralys Therapeutics Stock is Climbing - TipRanks
279,500 Shares in Mineralys Therapeutics, Inc. $MLYS Bought by Canada Pension Plan Investment Board - MarketBeat
Hedge Fund and Insider Trading News: Louis Bacon, Bill Ackman, Warren Buffett, Dan Loeb, Silver Point Capital, Starboard Value, Elliott Management, Mineralys Therapeutics Inc (MLYS), DuPont de Nemours Inc (DD), and More - Insider Monkey
Mineralys Therapeutics stock hits all-time high at 37.42 USD - Investing.com
What Makes Mineralys Therapeutics, Inc. (MLYS) a Strong Momentum Stock: Buy Now? - Yahoo Finance
Tuesday 9/9 Insider Buying Report: MLYS, KMTS - Nasdaq
Mineralys Therapeutics Stock (MLYS) Opinions on $175M Public Offering and Clinical Trial Results - Quiver Quantitative
Is Summit Therapeutics a Buy, Sell, or Hold Now? - AOL.com
Major Investment Alert: Mineralys Therapeutics Sees Huge Stock Purchase! - TipRanks
Mineralys Therapeutics (NASDAQ:MLYS) Shares Gap DownTime to Sell? - MarketBeat
Ra Capital Healthcare Fund buys Mineralys Therapeutics shares for $30m By Investing.com - Investing.com South Africa
Ra Capital Healthcare Fund buys Mineralys Therapeutics shares for $30m - Investing.com Nigeria
Buy Rating for Mineralys Therapeutics, Inc. Driven by Promising Phase 3 Results and Strong Financial Position - TipRanks
H.C. Wainwright reiterates Buy rating on Mineralys stock, citing lorundrostat potential - Investing.com Nigeria
Mineralys Therapeutics Shares Surge on Promising Trial Results - TipRanks
Drawdown in Mineralys Therapeutics Inc. May Be Nearing EndQuarterly Profit Summary & Breakout Confirmation Trade Signals - beatles.ru
Should value investors consider Mineralys Therapeutics Inc.July 2025 Trade Ideas & Real-Time Price Movement Reports - beatles.ru
Will Mineralys Therapeutics Inc. benefit from current market trendsMarket Performance Summary & Precise Buy Zone Identification - 뉴스영
Buy Rating Affirmed for Mineralys Therapeutics Due to Promising Hypertension Drug Data and Market Position - TipRanks
Mineralys Therapeutics (NASDAQ:MLYS) Reaches New 1-Year HighShould You Buy? - MarketBeat
Mineralys Therapeutics (NASDAQ:MLYS) Price Target Raised to $26.00 - MarketBeat
Mineralys Therapeutics prices upsized $250M stock offering - MSN
Jefferies expects Mineralys stock to trade up following AstraZeneca data - MSN
Mineralys Therapeutics, Inc. $MLYS Shares Sold by ADAR1 Capital Management LLC - MarketBeat
How moving averages guide Mineralys Therapeutics Inc. trading2025 Geopolitical Influence & Free Real-Time Volume Trigger Notifications - Newser
Is Mineralys Therapeutics Inc. affected by consumer sentiment2025 Volume Leaders & Reliable Volume Spike Trade Alerts - خودرو بانک
Is Mineralys Therapeutics Inc. undervalued by DCF analysisWeekly Trend Report & Smart Swing Trading Techniques - خودرو بانک
Mineralys reports positive subgroup data for hypertension drug By Investing.com - Investing.com Canada
Can Mineralys Therapeutics Inc. disrupt its industryJuly 2025 Gainers & Free Weekly Chart Analysis and Trade Guides - خودرو بانک
Nantahala Capital Management LLC Increases Stock Holdings in Mineralys Therapeutics, Inc. $MLYS - MarketBeat
Mineralys Therapeutics Inc Stock (MLYS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):